Trial Profile
HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease [EXTENSION OF 700046174]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2016
Price :
$35
*
At a glance
- Drugs Latrepirdine (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
- Acronyms HORIZON-PLUS
- 06 Mar 2013 New trial record